TABLE 4.

Predictors of the 6-week mortality in all candidaemic patients

Characteristics	HR (95% CI)	p	Adjusted HR (95% CI)	p
Mixed Candida/bacterial BSI	1.09 (0.67–1.78)	0.72	–	ND
Gram-positive bacteria	0.76 (0.42–1.39)	0.37	–	ND
Gram-negative bacteria	1.67 (0.86–3.25)	0.13	–	0.15
Co-morbidities
Chronic kidney disease	2.03 (1.11–3.72)	0.021	–	0.96
Charlson co-morbidity index ≥4	1.79 (1.13–2.85)	0.014	1.91 (1.17–3.13)	0.01
Risk factors for Candida infectiona
ICU residence	1.77 (1.12–2.80)	0.015	–	0.36
Neutropenia	1.46 (0.82–2.62)	0.20	–	0.08
Chemotherapy	1.56 (0.95–2.54)	0.08	–	0.15
Corticosteroids	1.59 (0.94–2.68)	0.09	–	0.27
Surgery	0.46 (0.24–0.88)	0.02	0.34 (0.17–0.65)	0.001
Hyperalimentation	1.72 (0.83–3.60)	0.15	-	0.31
Severity of illness
SOFA score ≥10	3.78 (2.33–6.12)	<0.001	3.00 (1.73–5.18)	<0.001
Pitt bacteraemia score ≥8	4.83 (2.80–8.33)	<0.001	6.98 (3.32–14.70)	<0.001
Mechanical ventilation	1.90 (1.19–3.02)	0.007	–	0.76
Continuous renal replacement therapy	1.90 (1.02–3.54)	0.04	–	0.07
Delay in initiation of antifungal therapy >72 h	1.87 (1.16–3.00)	0.01	2.03 (1.23–3.35)	0.006
Early central venous catheter removal	0.68 (0.41–1.13)	0.13	–	0.99
Persistent candidaemia at the last blood culture	5.87 (3.62–9.52)	<0.001	7.60 (4.36–13.25)	<0.001

BSI, bloodstream infection; HR, hazard ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment.

^aRisk factors within 30 days prior to candidaemia.